JDS-HF3.0 Supplementation on Menopause Related Quality of Life Outcomes in Postmenopausal Women (NCT07238478) | Clinical Trial Compass
RecruitingNot Applicable
JDS-HF3.0 Supplementation on Menopause Related Quality of Life Outcomes in Postmenopausal Women
United States250 participantsStarted 2025-05-14
Plain-language summary
The goal of this interventional study is to evaluate whether the study product can help improve quality of life and reduce common menopause symptoms-such as joint discomfort, hot flashes and night sweats-in women aged 50-70. The primary research question is whether taking the study product daily for 12 weeks can reduce the severity and frequency of menopause-related symptoms.
Who can participate
Age range
50 Years – 70 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Healthy biological females who are 50-70 years of age (inclusive).
. Have a body mass index (BMI) between 18.5 to 34.9 kg/m2 (inclusive).
. Self-reported as postmenopause. Defined as 12 months without a menstrual cycle in individuals who undergo "Natural" Menopause (Not Surgically or medically induced) and who have self-reported menopausal outcomes for the past 6 months.
. Have self-reported menopause related joint outcomes of moderate or severe severity according to a perceived discomfort greater or equal to 5 and less than 10 on a scale of 0-10 (participants rating their discomfort 5-9 will be included).
. Have self-reported \> or equal to 4 hot flashes on average per day.
. In good general health (no active or uncontrolled diseases or conditions) and able to consume the study product.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Change from Baseline in Menopause Related Quality of Life Outcomes
Timeframe: From enrollment to the end of study at 12 weeks
2
Change from Baseline in Menopause Related Quality of Life Outcomes
Timeframe: From enrollment to the end of study at 12 weeks
3
Change from Baseline in Menopause Related Quality of Life Outcomes
Timeframe: From enrollment to the end of study at 12 weeks
. Agree to refrain from treatments listed in Section 6.5 in the defined timeframe.
. Have reliable, stable access to Wi-Fi and a smart phone/device.
Exclusion criteria
. Individuals who are lactating, pregnant, or planning to become pregnant during the study.
. Active participation in a clinical trial.
. Use of any treatment for menopausal outcomes or other concomitant treatments for menopausal symptoms, joint health or at the discretion of the investigator. (Participants may be deemed ineligible at the discretion of the investigator if the medication may cause adverse interaction.)
. Have a known sensitivity, intolerability, or allergy to any of the study product or their excipients.
. Use of Glucosamine and/or Chondroitin for joint outcomes in the last 3 months prior to screening.
. Received a COVID-19 vaccine in the 2 weeks prior to screening or during the study period, current COVID-19 infections or currently have the post-COVID-19 condition as defined by World Health Organization (WHO) (i.e., individuals with a history of probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset of COVID-19 with symptoms that last for at least two months and cannot be explained by an alternative diagnosis).
. Have a positive medical history of heart disease, renal disease, hepatic impairment, or active systemic infection (i.e., Lyme disease, TB, HIV).
. History of cancer (except localized skin cancer without metastases) within two (2) years prior to screening.